ESR1 and breast carcinoma: Similarly, Dalm et al. observed, in a cohort of 684 patients with LN-negative breast cancer, a strong correlation between ER, SSTR, and PR and suggested the possibility to use SSTR radiolabeled ligands to guide breast cancer therapy in estrogen-resistant patients [127].